A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening

Mostrar otras versiones (1)

Drug development for specific antiviral agents against coronavirus disease 2019 (COVID-19) is still an unmet medical need as the pandemic continues to spread globally. Although huge efforts for drug repurposing and compound screens have put forth, only few compounds remain in late stage clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorshkov, Kirill, Vasquez, Desarey Morales, Chiem, Kevin, Ye, Chengjin, Tran, Bruce Nguyen, de la Torre, Juan Carlos, Moran, Thomas, Chen, Catherine Z., Martinez-Sobrido, Luis, Zheng, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282096/
https://www.ncbi.nlm.nih.gov/pubmed/34268508
http://dx.doi.org/10.1101/2021.07.03.450938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282096/
https://www.ncbi.nlm.nih.gov/pubmed/34268508
http://dx.doi.org/10.1101/2021.07.03.450938

Ejemplares similares